# A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

> **NCT00269399** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 237 (actual)

## Conditions studied

- Clostridium Infections
- Diarrhea

## Interventions

- **DRUG:** Rifaximin (Xifaxan)
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT00269399
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2019-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269399, "A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00269399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*